New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2013
08:12 EDTKERXKeryx Biopharmaceuticals announces filing of NDA for Ferric Citrate in Japan
Keryx Biopharmaceuticals announced that its Japanese partner, Japan Tobacco, has filed its New Drug Application with the Japanese Ministry of Health, Labour and Welfare for marketing approval of ferric citrate in Japan for the treatment of hyperphosphatemia in patients with chronic kidney disease. The NDA filing is supported by efficacy and safety data from several successfully completed Phase 3 studies in CKD patients with hyperphosphatemia in Japan. Under the license agreement with JT and its subsidiary Torii Pharmaceutical Co. within 30 days, Keryx will receive a non-refundable payment of $7M for the achievement of the NDA filing milestone.
News For KERX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 29, 2014
07:34 EDTKERXKeryx initiates pivotal Phase 3 study of Ferric Citrate
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use